Just a few days after FDA Commissioner Makary resigned, ally Tracy Beth Høeg is also leaving the agency. Her departure comes ...

Rina-S is the last candidate standing from Genmab’s $1.8 billion ProfoundBio acquisition two years ago, with the Danish ...

CREATE Medicines is working on a clinical-stage pipeline for cancer, while its autoimmune programs are still in preclinical ...

If Biogen has shown that tau can impact cognition, Denali’s technology—validated with an FDA approval in Hunter ...

Shares of REGENXBIO declined 37% on a mixed data readout and other updates from the company's first quarter earnings call ...

While Biogen’s tau-targeting therapy didn’t demonstrate improvement on a dementia severity scale, the company touted ...

Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...

The FDA has cleared BeOne Medicines’ BCL2 blocker sonrotoclax for the treatment of certain patients with mantle cell lymphoma ...

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...

Degron Therapeutics will have stiff competition in immunology, as Novartis inked a $5.7 billion agreement with Monte Rosa ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

The FDA's decision last year to make complete response letters public provides new insight into why therapies sometimes fail ...